共 11 条
[1]
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. P Rutgeerts,G D’Haens,S Targan. Gastroenterology . 1999
[2]
Cutaneousdrugerup-tiontoinfliximab:reportof4caseswithaninterfacedermatitispattern. VergaraG,SilvestreJF,BetllochI,etal. Archives of Dermatology . 2002
[3]
Delayedhypersen-sitivitytoinfliximab(remicade):re-infusionafter2-4yearinter-valwithouttreatment. HanauerSB,RutgeertsPJ,D’’HaensG,etal. Gastroenterology . 1999
[4]
Rapidresponsetoinfli-xmabinseverepustularpsoriasis,vonZumbuschtype. NewlandMR,WeinsteinA,KerdelF. IntJDer-matol . 2002
[5]
Theeffectivenessoftumornecrosisfactoralphaantibody(infliximab)intreatingrecalcitrantpsoriasis:are-portof2cases. O’’QuinnRP,MillerJL. Archives of Dermatology . 2002
[6]
Targetingtumornecrosisfactoralpha. LaDucaJR,GaspariAA. Dermatologic Clinics . 2001
[7]
Safetyofinfliximabinclinicaltrials. HanauerSB. Pharmacology and Therapeutics . 1999
[8]
Infliximab-inducedeczematoid-likepurpuraofdoucasandkapetenakis. WangLC,MedenicaMM,SheaCR,etal. JAmAcadDermatol . 2003
[9]
Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Devos SA,Van Den Bossche N,De Vos M,et al. Dermatology . 2003
[10]
Atopic dermatitis-like eruption precipitated by infliximab. Wright RC. Journal of the American Academy of Dermatology . 2003